BT200
Phase 3Small molecule
BT200 is one of 40 small molecule programs targeting Von Willebrand disease. It is currently in Phase 3.
2
Indications
3
Total Trials
2
Active Trials
39
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
42 competitors in Hemophilia B
#DrugCompanyPhaseTrials
1Recombinant Factor IX Coagulation
PfizerApproved
IB1001
MMedexus Pharma, Inc.
Phase 3
Translarna
PPTC Therapeutics
Phase 2
BENEFIX
PfizerPhase 3
Recombinant Factor IX
BBaxalta now part of Shire
Phase 3
Factor Ix
CSL BehringPhase 3
Rfix
PfizerPhase 3
Rix-FP
CSL BehringPhase 3
Nonacog Alfa
PfizerPhase 3
Rfixfc
BBioverativ Therapeutics Inc.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Von Willebrand disease1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for BT200. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- BBand Therapeutics